Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 79

Sort by

Sort Order Select

Journal Articles

Activation of AKT/mTOR Pathway in Ph+ Acute Lymphoblastic Leukemia (ALL) Leads to Non-Mutational Resistance

Afsar Ali Mian, BSc, MPhil, PhD, Usva Zafar, BSc, Oliver Ottmann, Prof, MD, Martin Ruthardt, MD, El-Nasir M A Lalani, BSc MBChB FRCPath PhDFHEA

Blood (2019) 134 (Supplement_1): 2570.

https://doi.org/10.1182/blood-2019-130898

Published: 2019

Journal Articles

Combination of Tigecycline and Homoharringtonine Synergistically Enhances Anti-Leukemia and Anti-MDS Effect Followed By Inhibiting Mitochondrial Translation through AKT/Mtorpathway and Downregulation of Anti-Apoptotic Proteins

Jie Jin, MD PhD, Hongyan Tong, Yang Haiyang

Blood (2019) 134 (Supplement_1): 5387.

https://doi.org/10.1182/blood-2019-128171

Published: 2019

Journal Articles

Metabolic Control and Systems Immunology in Blood Cell Development

Hongbo Chi, PhD

Blood (2019) 134 (Supplement_1): SCI-43.

https://doi.org/10.1182/blood-2019-121089

Published: 2019

Journal Articles

IGF1R-IRS1/2 Signaling Pathway Is a Potential Target for FLT3-Mutated Acute Myeloid Leukemia

Juan L Coelho-Silva, BSc, MSc, Diego A Pereira-Martins, MSc, Virginia Campos Silvestrini, BSc, MSc, Eduardo M Rego, MD PhD, Vitor Marcel Faca, PhD, João Agostinho Machado-Neto, PhD, Fabiola Traina, MD PhD

Blood (2019) 134 (Supplement_1): 2689.

https://doi.org/10.1182/blood-2019-132129

Published: 2019

Journal Articles

UCH-L1 bypasses mTOR to promote protein biosynthesis and is required for MYC-driven lymphomagenesis in mice

Sajjad Hussain, Tibor Bedekovics, Qiuying Liu, Wenqian Hu, Haeseung Jeon, Sarah H. Johnson, George Vasmatzis, Danielle G. May, Kyle J. Roux, Paul J. Galardy

Blood (2018) 132 (24): 2564–2574.

https://doi.org/10.1182/blood-2018-05-848515

Published: 2018

Includes: Supplemental data

Journal Articles

Precision Assessment of on- and Off-Target Effects of mTOR Kinase Inhibitors in a Mouse Model

Cuiqing Fan, PhD, Xiongwei Cai, PhD, Feng Zhang, PhDcandidate, Cindy Hochstetler, PhDcandidate, Xiaoyi Chen, PhD, Fukun Guo, PhD, Weidong Tian, PhD, Yi Zheng, PhD

Blood (2018) 132 (Supplement 1): 2632.

https://doi.org/10.1182/blood-2018-99-115225

Published: 2018

Journal Articles

Eosinophil Differentiation and Viability in Hypereosinophilia Is Impaired By Genetic and Pharmacologic Targeting of LCP1 and PKC Beta

Guangxin Ma, Deniz Gezer, MD, Oliver Herrmann, Msc, Andreas Reiter, MD, Mohamad Jawhar, Mirle Schemionek, Tim H. Brümmendorf, MD, Steffen Koschmieder, MD, Nicolas Chatain, PhD

Blood (2018) 132 (Supplement 1): 4320.

https://doi.org/10.1182/blood-2018-99-114646

Published: 2018

Journal Articles

Inhibition of Endothelial mTOR Drives Hematopoietic Stem Cell Aging

Jason M. Butler, PhD, Pradeep Ramalingam, MD

Blood (2018) 132 (Supplement 1): 1289.

https://doi.org/10.1182/blood-2018-99-117710

Published: 2018

Journal Articles

Role of mTORC1 and mTORC2 during Chronic Lymphocytic Leukaemia (CLL) Initiation and Progression

Natasha Malik, BSc, Karen Dunn, Owen Sansom, Prof, Alison M Michie, BSc, PhD

Blood (2018) 132 (Supplement 1): 3123.

https://doi.org/10.1182/blood-2018-99-116614

Published: 2018

Journal Articles

A Phase II Study to Determine the Safety and Efficacy of the Dual m-TORC Inhibitor AZD2014 and to Investigate Additional Toxicities in Combination with Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Toby A. Eyre, MBBChir, MRCP, Catherine Hildyard, MRCP, BA, Anesh Panchal, BSc, MSc, Aimee E Houlton, BSc, MSc, Louise Hopkins, BSc, MRes, Angela Hamblin, MD PhD, Kim Linton, MBChB PhD, Andrew Pettitt, FRCPath, PhD, Simon Rule, MD, Kate Cwynarski, PhD MD, Sally Barrington, MBBS, MSc, FRCP, FRCR, MD, David Wrench, MA, MBBChir, FRCPath, PhD, Andrew Davies, PhD, Graham Collins, MD PhD

Blood (2017) 130 (Supplement 1): 5210.

https://doi.org/10.1182/blood.V130.Suppl_1.5210.5210

Published: 2017

Journal Articles

MAPKAP1 (Sin1), a Key Component of the MTORC2 Complex, Confers Resistance to Sorafenib and Correlates with Adverse Clinical Outcomes in Acute Myeloid Leukemia

Joseph David Khoury, MD, Ioanna Xagoraris, MD, Nikolaos Tsesmetzis, MSc., Ida Hed Hed Myrberg, PhD, Thale Kristin Olsen, Siok Bian Ng, Wee-Joo Chng, MBBS, PhD FRCPath, FRCP, Benedict Yan, Chin Hin Ng, MD MRCP, Michael Andreeff, MD PhD, L. Jeffrey Medeiros, MD, Hagop M. Kantarjian, MD, Herold Nikolas, MD PhD, Dan Grander, MD PhD, George Rassidakis, MD PhD

Blood (2017) 130 (Supplement 1): 3964.

https://doi.org/10.1182/blood.V130.Suppl_1.3964.3964

Published: 2017

Journal Articles

Repurposing Dasatinib for Ibrutinib-Resistant Diffuse Large B-Cell Lymphoma

Claudio Scuoppo, PhD, Wang Jiguang, Mirjana Persaud, Sandeep Mittan, Laura Pasqualucci, MD, Raul Rabadan, Carla Grandori, Riccardo Dalla-Favera, MD

Blood (2017) 130 (Supplement 1): 3843.

https://doi.org/10.1182/blood.V130.Suppl_1.3843.3843

Published: 2017

Journal Articles

Suppression of mTOR Signaling Attenuates Apoptotic Effects Induced By the NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Acute Myeloid Leukemia Cells

Naxin Guo, PhD, Mary Nemer, Subanky Sivagnanalingam, Mitra Azadniv, PhD, Jason H. Mendler, MD PhD, Michael W. Becker, MD, Jane L. Liesveld, MD

Blood (2017) 130 (Supplement 1): 3820.

https://doi.org/10.1182/blood.V130.Suppl_1.3820.3820

Published: 2017

Journal Articles

Differential Gene Expression Using RNA Sequencing Between Elderly Acute Myeloid Leukemia (AML) Patients with Long Versus Short-Term Survival

Amy M Trottier, MD MSc, Adnan Mansoor, MD FRCPC, Carolyn J. Owen, MD MDes(UK), FRCPC, Ariz Akhter, PhD, Etienne Mahe, BSc, MD FRCPC, Michelle Geddes, MD FRCPC

Blood (2016) 128 (22): 1683.

https://doi.org/10.1182/blood.V128.22.1683.1683

Published: 2016

Journal Articles

Exploring the Function of Sestrin/Gator As Novel Regulators of Hematopoiesis

Nina Kurrle, PhD, Frank Schnütgen, PhD, Juliana Heidler, PhD, Ina Poser, PhD, Frank Wempe, PhD, Diego Yepes, PhD, Ilka Wittig, PhD, Thomas Oellerich, MD, Michael A Rieger, PhD, Harald von Melchner, MD PhD, Hubert Serve, MD

Blood (2016) 128 (22): 1484.

https://doi.org/10.1182/blood.V128.22.1484.1484

Published: 2016

Journal Articles

The Critical Roles of SIN1 in Platelet Activation and Myocardial Infarction

Yanyan Xu, PhDstudent, Xue Chen, PhD, Junling Liu, PhD

Blood (2016) 128 (22): 3715.

https://doi.org/10.1182/blood.V128.22.3715.3715

Published: 2016

Journal Articles

A Dose-Escalation (DE) Study with Expansion Evaluating Safety, Pharmacokinetics and Efficacy of the Novel, Balanced PI3K/mTOR Inhibitor PQR309 in Patients with Relapsed or Refractory Lymphoma

Graham P. Collins, MD PhD, Rakesh Popat, Anastasios Stathis, Fatime Krasniqi, MD PhD, Toby A. Eyre, MD, Chin Hin Ng, MD, Dima El-Sharkawi, MD, Christian Schmidt, MD, Andreas Wicki, MDPhD, Elena Ivanova, PhD, Debora Schmitz, PhD, Sasa Dimitrijevic, PhD, Martin H. Dreyling, MD PhD

Blood (2016) 128 (22): 5893.

https://doi.org/10.1182/blood.V128.22.5893.5893

Published: 2016

Journal Articles

Silencing c-Myc Translation As a Therapeutic Strategy through Targeting PI3K Delta and CK1 Epsilon in Hematological Malignancies

Changchun Deng, MD PhD, Mark Lipstein, Luigi Scotto, PhD, Xavier O Jirau Serrano, B.S., Michael Mangone, PhD, Shirong Li, PhD, Jeremie Vendome, PhD, Yun Hao, Xiaoming Xu, Xiaoping Liu, MD PhD, Ipsita Pal, PhD, Shi-Xian Deng, PhD, Nicholas P. Tatonetti, PhD, Suzanne Lentzsch, MD PhD, Barry Honig, PhD, Donald Landry, MD PhD, Owen A. O'Connor, MD PhD

Blood (2016) 128 (22): 291.

https://doi.org/10.1182/blood.V128.22.291.291

Published: 2016

Journal Articles

Interference of HMGB1 Lead to Increased Vulnerability of MM Cells to Dexamethasone and Doxorubicin

Xing Guo, M.MD, Donghua He, PhD, Jing Chen, M.MD, Xuanru Lin, M.MD, Qingxiao Chen, M.MD, Haimeng Yan, Xi Huang, M.MD, Yi Li, PhD, Li Yang, PhD, Enfan Zhang, M.MD, Yang Yang, PhD, Wenjun Wu, MD, Jingsong He, He Huang, MD PhD, Zhen Cai, MD PhD

Blood (2016) 128 (22): 2086.

https://doi.org/10.1182/blood.V128.22.2086.2086

Published: 2016

Journal Articles

Two strikes against CLL

Rosa Lapalombella

Blood (2016) 128 (4): 470–471.

https://doi.org/10.1182/blood-2016-06-719864

Published: 2016

NARROW

Activation of AKT/mTOR Pathway in Ph+ Acute Lymphoblastic Leukemia (ALL) Leads to Non-Mutational Resistance

Combination of Tigecycline and Homoharringtonine Synergistically Enhances Anti-Leukemia and Anti-MDS Effect Followed By Inhibiting Mitochondrial Translation through AKT/Mtorpathway and Downregulation of Anti-Apoptotic Proteins

Metabolic Control and Systems Immunology in Blood Cell Development

IGF1R-IRS1/2 Signaling Pathway Is a Potential Target for FLT3-Mutated Acute Myeloid Leukemia

UCH-L1 bypasses mTOR to promote protein biosynthesis and is required for MYC-driven lymphomagenesis in mice

Precision Assessment of on- and Off-Target Effects of mTOR Kinase Inhibitors in a Mouse Model

Eosinophil Differentiation and Viability in Hypereosinophilia Is Impaired By Genetic and Pharmacologic Targeting of LCP1 and PKC Beta

Inhibition of Endothelial mTOR Drives Hematopoietic Stem Cell Aging

Role of mTORC1 and mTORC2 during Chronic Lymphocytic Leukaemia (CLL) Initiation and Progression

A Phase II Study to Determine the Safety and Efficacy of the Dual m-TORC Inhibitor AZD2014 and to Investigate Additional Toxicities in Combination with Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)

MAPKAP1 (Sin1), a Key Component of the MTORC2 Complex, Confers Resistance to Sorafenib and Correlates with Adverse Clinical Outcomes in Acute Myeloid Leukemia

Repurposing Dasatinib for Ibrutinib-Resistant Diffuse Large B-Cell Lymphoma

Suppression of mTOR Signaling Attenuates Apoptotic Effects Induced By the NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Acute Myeloid Leukemia Cells

Differential Gene Expression Using RNA Sequencing Between Elderly Acute Myeloid Leukemia (AML) Patients with Long Versus Short-Term Survival

Exploring the Function of Sestrin/Gator As Novel Regulators of Hematopoiesis

The Critical Roles of SIN1 in Platelet Activation and Myocardial Infarction

A Dose-Escalation (DE) Study with Expansion Evaluating Safety, Pharmacokinetics and Efficacy of the Novel, Balanced PI3K/mTOR Inhibitor PQR309 in Patients with Relapsed or Refractory Lymphoma

Silencing c-Myc Translation As a Therapeutic Strategy through Targeting PI3K Delta and CK1 Epsilon in Hematological Malignancies

Interference of HMGB1 Lead to Increased Vulnerability of MM Cells to Dexamethasone and Doxorubicin

Two strikes against CLL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only